We use cookies to study and improve the user experience offered by the site. By continuing to browse the site you are agreeing to our cookie policy.

News

Dr. Josep Maria Ribera
04/25/2017

A Josep Carreras Institute research team reveals the effectiveness of a new treatment for acute lymphoblastic leukaemia

•  A Josep Carreras Leukaemia Research Institute (IJC) acute lymphoblastic leukaemia (ALL) research team, led by Dr. Josep Maria Ribera, has participated in a study published in the prestigious journal, The New England Journal of Medicine.

• The study shows that treatment with blinatumomab significantly prolongs the life expectancy of adult patients with certain kinds of leukaemia, in comparison with standard treatment with chemotherapy.

•  This discovery is an important step forward for improving the prognosis for adult ALL patients, a kind of leukaemia with an incidence of 30 new cases per million every year in Spain.

More
Webpage updated 10/16/2019 13:23:15